Image credit: Eyexora
Eyexora is a global ophthalmology company pioneering a hub-and-spoke model to accelerate innovation in eye care, has launched a company to accelerate innovation in ophthalmology using a hub-and-spoke model. The company is building a global portfolio starting with collaborations in Singapore and Europe, with its initial assets in-licensed from the Singapore Eye Research Institute (SERI).
Eyexora’s seed financing was led by Singapore's life sciences investor ClavystBio, with participation from leading ophthalmology experts. The company’s mission is to advance a diversified portfolio of anterior and posterior segment therapeutics, as well as ophthalmic devices, in a $50 billion global market serving more than two billion patients.
Eyexora overcomes the inefficiencies of traditional drug development by centralizing scientific, clinical, regulatory, and commercial expertise in a shared operational “hub” that deploys across its subsidiaries. Each subsidiary houses a distinct therapeutic or technology program, enabling scalable growth while reducing risk.
The model is designed to balance validated mechanisms with high impact “moonshots,” replenished with clinic-ready assets sourced from global clinician-scientists and academic incubators. Eyexora is headquartered in the U.S. with plans to open global subsidiaries to best support its business model.
“Traditional ophthalmology drug development has been dominated by single-asset pipelines, making innovation slow, costly, and high-risk,” said Dr. Theresa Heah, CEO, Eyexora. “Eyexora is built to change that by bringing the right structure, global partnerships, and deep domain expertise together to deliver transformative treatments faster, smarter, and at scale.”
Professor Jod S. Mehta, Executive Director of the Singapore Eye Research Institute (SERI) said “This collaboration reflects SERI’s commitment to translating cutting-edge science into clinical solutions and underscores Singapore’s role as a hub for world-class translational eye research.”
